Quanterix Q4 revenue up 22% to $31.5M, net loss narrows; guides FY2024 revenue $139-144M

Quanterix Corp

2023-FY EPS reported -$0.86 revenue$122,368,000

Q4 revenue $31.5M (+22% YoY); GAAP gross margin 53.2% (up from 48.8%); net loss $12.4M vs $18.6M.
Full-year 2023 revenue $122.4M (+16%); GAAP gross margin 57.7% vs 44.4%; net loss $32.3M vs $96.7M.
Completed corporate transformation; new assays in production. Collaborations with Mayo Clinic, Mass General Brigham, others for Alzheimer's diagnosis.
2024 guidance: revenue $139-144M (research-only), GAAP gross margin 57-61%, non-GAAP 51-55%, cash usage $25-30M.
Eli Lilly launched pTau217 blood-based diagnostic test on Quanterix platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quanterix Corp reported the fourth quarter and twelve months ended December 31, 2023 results: revenue $31.5 million, net income Net loss was $12.4 million. Guidance initiated.

Period: the fourth quarter and twelve months ended December 31, 2023
Revenue: $31.5 million
Net income: Net loss was $12.4 million
Guidance: initiated
Result: reported results

Exact text from the filing

biomarker testing to support the rollout of new Alzheimer’s therapies and to aid providers in the diagnosis of the disease.” Fourth Quarter Financial Highlights ● Revenue was $31.5 million, a 22% increase from $25.8 million for the corresponding prior year period. ● GAAP gross margin was 53.2% as compared to 48.8% for the corresponding prior year period. Non-GAAP

View on SEC.gov

53 earnings releases filed in the last 30 days. Browse all earnings releases →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-002184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.